FDA Approves Libtayo(R) (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma

September 29, 2018

https://www.prnewswire.com/news-releases/fda-approves-libtayo-cemiplimab-rwlc-as-first-and-only-treatment-for-advanced-cutaneous-squamous-cell-carcinoma-300721188.html